Kobo Biotech Ltd

Kobo Biotech Ltd (531541)


Key Stats

Day's Price Range
52-Week Price Range
1 Month Return-0.2 %
3 Month Return-0.59 %
1 Year Return7.87 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

Rank 293
Rank 297
Rank 241
Dividend Yield
Rank 176
Rank 445
Price To Book Ratio
Debt To Asset
Rank 31

Company Information

Avon Organics promoted by P R Agarwal Rajesh Agarwal and G S Sidhu was incorporated in August 1993 to manufacture diketene and its derivatives Monomethyl AcetoncetamideMMA and Methyl AcetoacetateMAA. The companys 1200 tpa Diketene manufacturing faciltiy located at Sadashivpet in Andhrapradesh and the products of it were used in pigments pharmaceuticals and pesticides.The company has a tripartite technical knowhow agreement with Shanghai Machinery Equipment Import and Export Corporation SMEC representative of Shanghai Peng Pu Chemical Works SPCW and Xytel Technologies Partnership XTP US. XTP shall be the technical supervisor for the transfer of technology while SMEC shall supply the technical knowhow.The company has bagged the award for the Best New Product manufactured in the State of Andhra Pradesh as awarded by the Federation of Andhra Pradesh Chamber of Commerce and Industry and also certified as an ISO 9002 company by American Quality Asseassors accredited with ANSIRAB for the manufacturing and marketing MMAA MMAE DEA EEAA and Aralydes.The company had developed technology for recovery of Diketene from sludge. The company has also diversified into BioTechnology where the value addition is high. To part finance its biotech project the company has made a preferential issue of 1800000 Equity shares at Rs. 38.75 each aggregating to Rs. 697.50 lacs and issued 400000 warrants convertible into 400000 equity shares during the year 19992000.The BioTechnology Plant is located at SolapurMaharashtra for manufacture of Ephedrine and PseudoEphedrine with an installed capacity of 150 MT p.a. The plant has commenced operations during April 2001. The biotech division produces Pharmaceutical intermediates i.e Pseudoephedrine and ephedrine. The company has signed two longterm export contracts to supply fixed quantities of Pseudoephedrine and is in talks with a few more MNCs for long term contracts during the year 200102. The companys biotech division is pursuing USFD approval which will enable it to enter into regulated markets.The company is all set to introduce two high value added intermediates in its Diketene division.The company has already completed trial production for these two pharmaceutical products and is ready for commercial launch.The company is expected an additional turnover of Rs.12 crores from these products from the year 200506.
OrganisationKobo Biotech Ltd